3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Lymphoma
113
Leukemia
80
Precursor Cell Lymphoblastic Leukemia-Lymphoma
61
Lymphoma, Non-Hodgkin
59
Multiple Myeloma
56
Leukemia, Myeloid, Acute
56
Lymphoma, Large B-Cell, Diffuse
55
Hodgkin Disease
48
Myelodysplastic Syndromes
43
Burkitt Lymphoma
43
Lymphoma, Follicular
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Lymphoma, Mantle-Cell
40
Breast Neoplasms
35
Lymphoma, Large-Cell, Immunoblastic
34
Sarcoma
27
Neoplasms, Plasma Cell
27
Central Nervous System Neoplasms
25
Lymphoma, B-Cell, Marginal Zone
24
Dendritic Cell Sarcoma, Interdigitating
19
Recurrence
18
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Ovarian Neoplasms
16
Neuroblastoma
16
Myeloproliferative Disorders
16
Leukemia, Myeloid, Chronic-Phase
16
Leukemia, Myeloid, Accelerated Phase
15
Congenital Abnormalities
15
Neutropenia
13
Lung Neoplasms
13
Interventions
Rituximab
5
Valganciclovir
3
Zidovudine
2
Methotrexate
2
Leucovorin
2
Doxorubicin
2
merphos
1
cc-486
1
avelumab
1
apatinib
1
Vincristine
1
Valacyclovir
1
Vaccines
1
Tomography, X-Ray Computed
1
Prednisone
1
Nivolumab
1
Kidney Transplantation
1
Interferons
1
Hydroxyurea
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Etoposide
1
Echocardiography
1
EPOCH protocol
1
Docetaxel
1
Dexamethasone
1
Cyclophosphamide
1
Cisplatin
1
Caves
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Epstein-Barr Virus Infections
×
Filgrastim
×
Clear all
NCT00953420
2017-08-18
CADEN
Baylor College of Medicine
Phase 2
Completed
20 enrolled